Results 91 to 100 of about 2,404 (154)

Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

Eurosurveillance
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants 
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Talking to parents about Nirsevimab [poster]

Nirsevimab is an immunisation to protect from Respiratory syncytial virus (RSV).
Health Protection Surveillance Centre (HPSC)
core  

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France

International audienceBackground Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long‐acting monoclonal antibody to prevent RSV‐associated lower respiratory tract infections (LRTI) was ...
Ploin, Dominique, Butin, Marine, Horvat, Côme, Javouhey, Etienne, Hassenboehler, Juliette, Casalegno, Jean‐sebastien, Gillet, Yves, Plaisant, Franck, Ragouilliaux, Corinne, Nunes, Marta C., Chauvel, Cécile, Chakra, Claire Nour Abou   +11 more
core   +1 more source

Analysis of Beyfortus^® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

Current Issues in Molecular Biology
Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj   +1 more source

Análisis retrospectivo de la epidemiología, gravedad y evolución clínica de la bronquiolitis en la Unidad de Cuidados Intensivos Pediátricos: antes y después de Nirsevimab. [PDF]

Introducción: La introducción de Nirsevimab ha supuesto un cambio en el paradigma de la bronquiolitis por virus respiratorio sincitial (VRS).Objetivos: Analizar la epidemiología, incidencia y gravedad de los pacientes ingresados por bronquiolitis en la ...
Ramos Fuentes, Feliciano, Hernando Larroy, Alicia, García Íñiguez, Juan Pablo   +2 more
core  

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants:An Analysis Including All-Infant Protection [PDF]

Objectives: This study aimed to assess the cost effectiveness of nirsevimab, a recently authorized monoclonal antibody (mAb) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), in comparison with the ...
Postma, Maarten J., Boersma, Cornelis, van der Pol, Simon; id_orcid, Zeevat, Florian, van der Pol, Simon, Kieffer, Alexia, Postma, Maarten J.; id_orcid   +6 more
core   +1 more source

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024 [PDF]

Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer\u27s maternal RSV vaccine.
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Paden, Clinton, Clopper, Benjamin R, Thornburg, Natalie J, Dawood, Fatimah S, Sahni, Leila C, Englund, Janet A, Atherton, Lydia, Schlaudecker, Elizabeth P, Schuster, Jennifer E, Michaels, Marian G, Aggarwal, Megha, Stewart, Laura S, Halasa, Natasha B, Staat, Mary A, Piedra, Pedro A, Selvarangan, Rangaraj, Roychoudhury, Pavitra, Derado, Gordana, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Tannis, Ayzsa, Moline, Heidi L, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, New Vaccine Surveillance Network Collaborators   +30 more
core   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source